CAR T: Further Questions and Ongoing Research Scientists and clinicians alike are excited about this new therapy that may offer extended survival to certain patients who have exhausted their options …
CAR T-Cell Therapy HCP Guide – Further Questions and Ongoing Research Read More
There is some experimental work using chimeric antigen receptor engineered T cells (CAR-T cells) for therapy to target cancer stem cells. What CD receptor is being considered an attractive therapeutic …
StatPearls Question of the Week – #10 Read More
“The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee unanimously voted to recommend approval for CTL019, an experimental cancer drug that belongs to a class of drugs called CAR …
July 12, 2017 – Novartis CAR-T Cell Therapy One Step Closer to FDA Approval Read More
Published on Aug 4, 2017 Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians …
VIDEO: Dr. Roboz on Challenges With CAR T-cell Therapy in ALL Read More
July 31, 2017 (Medical News Today) A lack of understanding of molecular mechanisms which let cancer cells escape detection from the immune system is a reason why existing chemotherapy and …
Cell mechanism discovery could lead to ‘fundamental’ change in leukemia treatment Read More
July 19, 2017 (Medical News Today) Following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy, researchers presented that 70 percent of patients with the most common adult leukemia had tumor …
CAR T-cell therapy for leukemia leads to remissions in clinical trial Read More
July 1, 2017 (Medical News Today) The cancer drug, rituximab, is not a chemotherapy, but a monoclonal antibody therapy that uses antibodies which stick to specific cells or proteins and …
Human antibody bolsters cancer drug performance Read More
September 8, 2016 (HealthDay News) Researchers identify treatment characteristics that correlate with therapeutic response, toxicity Immunotherapy with CD19 chimeric antigen receptor (CAR)-modified T cells in a defined CD4+/CD8+ ratio can …
Remission Up With T Cell Therapy for Non-Hodgkin’s Lymphoma Read More
Published on Jul 21, 2017 Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck …
VIDEO: CAR T-Cell Therapy in Head and Neck Cancer Read More
July 3, 2017 (Medical News Today) Overall, the immune system does a remarkable job defending the body from disease-causing agents. When it comes to cancer, however, it falls short. Niroshana …
New insights into why the immune system fails to see cancer Read More